VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

In a Crowded Field, High-Intensity Focused Ultrasound Stakes a Claim

Tony Berberabe, MPH @OncBiz_Wiz
Published: Tuesday, Feb 02, 2016
Scott Eggener, MD

Scott Eggener, MD

The landscape for the patient with localized prostate cancer is filled with both new and exciting treatments. With better methods to screen, improved imaging scans to determine physical location and extent of cancer, and even active surveillance (AS), there are many options to consider.

Despite these advances, however, no consensus has emerged regarding the optimal treatment for the most common patient with prostate cancer: the man with clinically localized stage T1 to T2 disease with no regional lymph node or distant metastasis (T1 to T2N0-NxM0). Of the 234,460 men in the United States diagnosed with prostate cancer annually, 91% have localized disease, according to the American Urological Association (AUA).

“A substantial proportion of men who are diagnosed with prostate cancer can very safely and effectively just be monitored and don’t require any treatment,” said Scott Eggener, MD, associate professor of surgery and co-director, Prostate Cancer Program at the University of Chicago. Traditional treatments like radical prostatectomy or radiation are still the standards of care with the best known, long-term outcomes for cure, but there are adverse effects associated with each. He noted that whole gland treatment of prostate cancer carries a risk of incontinence and sexual dysfunction.

Appropriately selected patients who choose AS, monitoring of their cancer without immediate treatment, can expect excel-lent long-term results but may experience anxiety that stems from not treating a diagnosed cancer. The AUA notes that patients with lower-risk tumors (low Gleason score, PSA level, and clinical stage) could be candidates for this management strategy. Several studies have shown that patients with lower- grade, localized prostate cancer have an extremely low risk for metastatic progression within the first 10–15 years after the diagnosis, although approximately 30% to 50% of men will re-quire surgery or radiation at some point after initiating AS.

Parameters for surveillance is a discussion that needs to occur between the patient and his physician before this course of action is undertaken. Currently, providing evidence-based recommendations for when to intervene in patients with a long life expectancy are not possible since markers of disease progression are poorly validated. Most reports describe a clinical strategy that includes regular prostate-specific antigen (PSA) level measurement and digital rectal examination with a periodic repeat prostate biopsy along with an option of more active therapy if biochemical (increasing PSA) or histopathologic (in-creased tumor grade or volume) progression occur.

Focal therapy has been proposed in recent years as a means of filling the gap in the treatment spectrum between whole gland treatment and AS. Many believe that for patients with intermediate-risk disease, focal therapy is an attractive option for maximizing quality of life by avoiding the effects of whole gland radiation or surgery while alleviating the anxiety and uncertainty of AS by targeting and ablating the tissue that contains disease which may pose a real threat to the patient. Ablation of the entire prostate or targeted ablation of only the malignant parts of the prostate are possible by a variety of technologies, including cryoablation, radiofrequency, microwave, laser, vascular targeted, and electroporation devices. One new option in the United States is the use of focal therapy using high-intensity focused ultrasound (HIFU).

“There’s been a movement to consider more minimally invasive approaches, such as treating part of the prostate, rather than the entire prostate, which may lead to quicker recovery and fewer side effects but has not been established with long-term cancer-related outcomes,” said Eggener.

Enter HIFU

Ultrasound energy is focused at a specific location in the prostate gland called the focal point. At the focal point, prostate tissue is heated to nearly 195°F (90°C). The tissue at the focal point is destroyed, but the surrounding tissue remains un-harmed. Because the technology uses ultrasound energy, not radiation, to destroy targeted tissue, the procedure can be repeated if necessary. The minimally invasive procedure can be used to ablate prostates up to 40 cm3 in volume without previously performing a transurethral resection of the prostate procedure.

Tissue analysis is conducted via radio frequency (RF). An RF signal is sent to a targeted ablation site prior to delivery of HI-FU and then another signal is sent after delivery of HIFU to the same site. The device calculates the change that took place and displays it on the screen. Tissue changes are quantified based on a comparison of RF ultrasound pulse-echo signals at each ablation site.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x